Free Trial
NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

Sangamo Therapeutics logo
$1.95 -0.01 (-0.51%)
(As of 11/20/2024 ET)

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Key Stats

Today's Range
$1.89
$2.11
50-Day Range
$0.78
$2.87
52-Week Range
$0.30
$3.18
Volume
6.70 million shs
Average Volume
12.91 million shs
Market Capitalization
$406.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Moderate Buy

Company Overview

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Sangamo Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
44th Percentile Overall Score

SGMO MarketRank™: 

Sangamo Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 672nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Sangamo Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Sangamo Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.50) to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sangamo Therapeutics is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sangamo Therapeutics is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sangamo Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Sangamo Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.10% of the outstanding shares of Sangamo Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sangamo Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sangamo Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sangamo Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sangamo Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.10% of the outstanding shares of Sangamo Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sangamo Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sangamo Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Sangamo Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    28 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.
  • MarketBeat Follows

    20 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.80% of the stock of Sangamo Therapeutics is held by insiders.

  • Percentage Held by Institutions

    56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sangamo Therapeutics' insider trading history.
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGMO Stock News Headlines

What is HC Wainwright's Estimate for SGMO FY2028 Earnings?
Wells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
Q3 2024 Sangamo Therapeutics Inc Earnings Call
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Sangamo options imply 21.0% move in share price post-earnings
See More Headlines

SGMO Stock Analysis - Frequently Asked Questions

Sangamo Therapeutics' stock was trading at $0.5433 at the start of the year. Since then, SGMO stock has increased by 258.9% and is now trading at $1.95.
View the best growth stocks for 2024 here
.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The biopharmaceutical company had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative trailing twelve-month return on equity of 264.16%.

Sangamo Therapeutics' top institutional shareholders include Wasatch Advisors LP (9.34%), Geode Capital Management LLC (1.02%), Jacobs Levy Equity Management Inc. (0.71%) and Charles Schwab Investment Management Inc. (0.53%). Insiders that own company stock include Biogen Inc and John Markels.
View institutional ownership trends
.

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), MSP Recovery (LIFW) and Abrdn Asia-Pacific Income Fund (FAX).

Company Calendar

Last Earnings
11/12/2024
Today
11/20/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/12/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
480
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$10.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+259.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-257,830,000.00
Net Margins
-257.87%
Pretax Margin
-257.89%

Debt

Sales & Book Value

Annual Sales
$176.23 million
Cash Flow
$0.04 per share
Book Value
$0.47 per share

Miscellaneous

Free Float
202,805,000
Market Cap
$406.87 million
Optionable
Optionable
Beta
1.10

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:SGMO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners